Diabetes mellitus ve komplikasyonlarının tanı,tedavi ve izlem ...

23. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin
A1C measurement: American Diabetes Association, European Association for the Study of Diabetes,
International Federation of Clinical Chemistryand Laboratory Medicine, and the International Diabetes
Federation. Diabetes Care 2007;30:2399–400.
24. Cryer PE, Axelrod L, Grossman AB, et al. The Endocrine Society’s Clinical Practice Guidelines.
Evaluation and management of adult hypoglycemic disorders. J Clin Endocrinol Metab 2009;94:709-
28.
25. Davidson JK (Editor). Clinical Diabetes Mellitus: A Problem-Oriented Approach. Third Edition. Thieme,
New York, 2000.
26. DeFronzo RA, Ferrannini E, et al (Editors). International Textbook of Diabetes Mellitus. Volume 1-2.
Third Edition. John Wiley & Sons, Chichester, 2004.
27. DeGroot LJ, Grossman AB, Marshall JC, et al (Editors). Endocrinology. Volume 1. Fifth Edition.
Saunders-Elsevier, Philadelphia, 2006.
28. Del Prato S, Felton A-M, Munro N, et al. The Global Partnership for Effective Diabetes Management.
Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic
goal. Int J Clin Pract 2005;59:1345-55.
29. Diabetes Control and Complications Trial Research Group. The effects of intensive diabetes treatment
on the development and progression of long-term complications in insulin-dependent diabetes
mellitus. N Engl J Med 1993;329:977-86.
30. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course
of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications
trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes
complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169):1307-16.
31. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J
Med. 2008 Jun 12;358(24):2630-3.
32. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators,
Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired
glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368(9541):1096-
105. Erratum in: Lancet 2006;368(9549):1770.
33. Droumaguet C, Balkau B, Simon D, et al. Use of HbA1c in predicting progression to diabetes in French
men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR).
Diabetes Care 2006;29:1619–25.
34. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with
type 2 diabetes. N Engl J Med 2009;360:129-39.
35. Edelman D, Olsen MK, Dudley TK, et al. Utility of hemoglobin A1c in predicting diabetes risk. J Gen
Intern Med 2004;19:1175–80.
36. Equal Employment Opportunity Commission, “Questions and Answers About Diabetes in the Workplace
and the Americans with Disabilities Act (ADA)” Oct. 29, 2003 (‘http://www.eeoc.gov/facts/diabetes.html’.
26 May 2008).
37. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.
38. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow- up report on the
diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–7.
39. Fisher N (Editor). Heart Disease and Diabetes. Martin Dunitz, London, 2003.
40. Fonseca VA (Editor). Clinical Diabetes: Translating Research into Practice. Saunders-Elsevier Inc,
Philadelphia, 2006.
172 | DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU